Jaguar Health

191 articles about Jaguar Health

• TAG Investment Bankers Ltd. Issues Analyst Report on Jaguar Health

  5/11/2022

  Jaguar Health, Inc. announced that TAG Investment Bankers Ltd. issued an analyst report today on the company.

• Jaguar Health Announces Launch of Mytesi Telehealth Program

  5/11/2022

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company's telehealth program went live on May 6, 2022 for Mytesi (crofelemer), Jaguar's FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

• Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials

  5/10/2022

  Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided company updates and reported consolidated first quarter 2022 financial results.

• Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates

  5/5/2022

  Jaguar Health, Inc. announced that company management will host an investor webcast on Tuesday, March 10, 2022, at 8:30 a.m. Eastern Time to review first-quarter 2022 financials and provide corporate updates.

• UPDATED RELEASE: Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates

  5/5/2022

  Jaguar Health, Inc. announced that company management will host an investor webcast on Tuesday, May 10, 2022, at 8:30 a.m. Eastern Time to review first-quarter 2022 financials and provide corporate updates..

• Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs

  5/3/2022

  Jaguar Health, Inc. announced that it has completed filing of the final regulatory section with the U.S. Food and Drug Administration's Center for Veterinary Medicine to support conditional new animal drug approval of the company's oral plant-based drug candidate Canalevia to treat exercise-induced diarrhea in dogs.

• Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

  4/27/2022

  Jaguar Health, Inc. announced that Canalevia-CA1, the company's prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs, is now available from multiple leading veterinary distributors in the U.S. Canalevia-CA1 received conditional approval from the FDA on December 21, 2021.

• Jaguar Health to Present at the NobleCon18 Investor Conference on April 21, 2022

  4/20/2022

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, Jaguar's president, founder, and CEO, will present at NobleCon18 - Noble Capital Markets' Eighteenth Annual Investor Conference at the Hard Rock Hotel & Casino in Hollywood, Florida on Thursday, April 21, 2022, at 11:00 AM Eastern.

• Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)

  4/15/2022

  Jaguar Health, Inc. announced today that the Company's New Employee Inducement Award Plan.

• Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About Chemotherapy-Induced Diarrhea (CID) in Dogs on April 12th

  4/6/2022

  Jaguar Health, Inc. today announced that the company is hosting a dinner and tableside discussion for U.S. veterinary oncologists in Puerto Vallarta, Mexico from 5:30 PM - 10:00 PM on Tuesday, April 12, 2022, the final day of the Veterinary Cancer Society (VCS) Mid-Year Conference.

• Jaguar Health Announces Appointment of Pravin Chaturvedi, Ph.D., as Chief Scientific Officer

  4/5/2022

  Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Pravin Chaturvedi, PhD, a pharmaceutical veteran and leading clinical development expert, has been appointed Chief Scientific Officer (CSO) and Chair of the Scientific Advisory Board (SAB) of Jaguar.

• Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets

  3/31/2022

  Jaguar Health, Inc. announced that the company has entered an agreement with Quadri Pharmaceuticals Store LLC that grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for specified human indications of crofelemer in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates.

• Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast

  3/14/2022

  Jaguar Health, Inc. announced that the recording of the company's March 14, 2022, investor webcast regarding company updates and reported consolidated financial results for the year ended December 31, 2021 can be accessed by clicking here.

• Jaguar Health Provides Company Updates and Reports 2021 Financials

  3/11/2022

  Jaguar Health, Inc. provided company updates and reported consolidated financial results for the year ended December 31, 2021.

• Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates

  3/7/2022

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Monday, March 14, 2022, at 8:30 a.m. Eastern Time to review fourth-quarter 2021 financials and provide corporate updates.

• Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas

  3/1/2022

  Jaguar Health, Inc. announced that the company is hosting a treatment forum for veterinarians about chemotherapy-induced diarrhea in dogs at the Mandalay Bay Resort and Casino in Las Vegas on Sunday, March 6, 2022 from 5:30 PM - 7:30 PM Pacific Time during the Western Veterinary Conference, which is being held at the same location.

• Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs

  2/16/2022

  Jaguar Health, Inc. announced that it has submitted a request to the U.S. Food and Drug Administration's Center for Veterinary Medicine for Minor Use/Minor Species designation for the company's oral plant-based drug candidate Canalevia™ for treatment of exercise-induced diarrhea in dogs.

• Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency

  2/15/2022

  Jaguar Health today announced that Napo Therapeutics has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA).

• Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs

  2/10/2022

  Jaguar Health, Inc., under its Jaguar Animal Health tradename for the veterinary market, announced that it has completed filing of the final major regulatory section with the U.S. Food and Drug Administration's Center for Veterinary Medicine to support conditional new animal drug approval of the company's oral plant-based drug candidate Canalevia to treat exercise-induced diarrhea in dogs.

• Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)

  2/1/2022

  Jaguar Health, Inc. (NASDAQ:JAGX) and Napo Pharmaceuticals, the company's wholly owned subsidiary, today announced the completion of a third-party, investigator-initiated preclinical enterocyte.